Fulgent Genetics, Inc. (FLGT) Q2 FY26 Earnings Call

Billing-system execution cut guidance despite acquisition-led growth and continued oncology pipeline progress.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Length31 minutes
EPS$-0.88
EPS consensus$-0.79

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26 · Q4 FY25

All FLGT earnings · Back to FLGT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.